246 related articles for article (PubMed ID: 23849341)
21. De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infections.
Masterton RG; Casamayor M; Musingarimi P; van Engen A; Zinck R; Odufowora-Sita O; Odeyemi IA
J Med Econ; 2013 Nov; 16(11):1344-56. PubMed ID: 24003830
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.
Sohn HS; Lee TJ; Kim J; Kim D
Clin Ther; 2009 May; 31(5):1105-15; discussion 1066-8. PubMed ID: 19539111
[TBL] [Abstract][Full Text] [Related]
23. Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: a retrospective observational cohort study of the Mycoses Study Group (MSG-12).
Chiotos K; Vendetti N; Zaoutis TE; Baddley J; Ostrosky-Zeichner L; Pappas P; Fisher BT
J Antimicrob Chemother; 2016 Dec; 71(12):3536-3539. PubMed ID: 27494929
[TBL] [Abstract][Full Text] [Related]
24. Cost and resource utilization associated with fluconazole as first-line therapy for invasive candidiasis: a retrospective database analysis.
Craver CW; Tarallo M; Roberts CS; Blanchette CM; Ernst FR
Clin Ther; 2010 Dec; 32(14):2467-77. PubMed ID: 21353115
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials.
Kullberg BJ; Vasquez J; Mootsikapun P; Nucci M; Paiva JA; Garbino J; Yan JL; Aram J; Capparella MR; Conte U; Schlamm H; Swanson R; Herbrecht R
J Antimicrob Chemother; 2017 Aug; 72(8):2368-2377. PubMed ID: 28459966
[TBL] [Abstract][Full Text] [Related]
26. Anidulafungin versus fluconazole for invasive candidiasis.
Reboli AC; Rotstein C; Pappas PG; Chapman SW; Kett DH; Kumar D; Betts R; Wible M; Goldstein BP; Schranz J; Krause DS; Walsh TJ;
N Engl J Med; 2007 Jun; 356(24):2472-82. PubMed ID: 17568028
[TBL] [Abstract][Full Text] [Related]
27. Treatment of invasive candidiasis: between guidelines and daily clinical practice.
Tagliaferri E; Menichetti F
Expert Rev Anti Infect Ther; 2015 Jun; 13(6):685-9. PubMed ID: 25818660
[TBL] [Abstract][Full Text] [Related]
28. Anidulafungin: a new echinocandin with a novel profile.
Vazquez JA
Clin Ther; 2005 Jun; 27(6):657-73. PubMed ID: 16117974
[TBL] [Abstract][Full Text] [Related]
29. Candidemia in the intensive care unit: analysis of direct treatment costs and clinical outcome in patients treated with echinocandins or fluconazole.
Heimann SM; Cornely OA; Wisplinghoff H; Kochanek M; Stippel D; Padosch SA; Langebartels G; Reuter H; Reiner M; Vierzig A; Seifert H; Vehreschild MJ; Glossmann J; Franke B; Vehreschild JJ
Eur J Clin Microbiol Infect Dis; 2015 Feb; 34(2):331-8. PubMed ID: 25213718
[TBL] [Abstract][Full Text] [Related]
30. Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome.
Reboli AC; Shorr AF; Rotstein C; Pappas PG; Kett DH; Schlamm HT; Reisman AL; Biswas P; Walsh TJ
BMC Infect Dis; 2011 Sep; 11():261. PubMed ID: 21961941
[TBL] [Abstract][Full Text] [Related]
31. Comparative efficacy of echinocandins and nonechinocandins for the treatment of Candida parapsilosis Infections: a meta-analysis.
Kale-Pradhan PB; Morgan G; Wilhelm SM; Johnson LB
Pharmacotherapy; 2010 Dec; 30(12):1207-13. PubMed ID: 21114387
[TBL] [Abstract][Full Text] [Related]
32. Cost-utility analysis of caspofungin and fluconazole for primary treatment of invasive candidiasis and candidemia in Ethiopia.
Gebretekle GB; Fentie AM; Gebremariam GT; Ali EE; Erku DA; Alemayehu T; Abebe W; Sander B
BMC Health Serv Res; 2022 Oct; 22(1):1302. PubMed ID: 36309674
[TBL] [Abstract][Full Text] [Related]
33. [Therapy of candidemia and invasive candidiasis according to guidelines].
Glöckner A
Mycoses; 2010 May; 53 Suppl 1():30-5. PubMed ID: 20433654
[TBL] [Abstract][Full Text] [Related]
34. Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study.
van der Geest PJ; Hunfeld NG; Ladage SE; Groeneveld AB
BMC Infect Dis; 2016 Sep; 16():490. PubMed ID: 27634140
[TBL] [Abstract][Full Text] [Related]
35. Antifungal step-down therapy based on hospital intravenous to oral switch policy and susceptibility testing in adult patients with candidaemia: a single centre experience.
Bal AM; Shankland GS; Scott G; Imtiaz T; Macaulay R; McGill M
Int J Clin Pract; 2014 Jan; 68(1):20-7. PubMed ID: 24341299
[TBL] [Abstract][Full Text] [Related]
36. [Cost analysis of 3 candins in the treatment of invasive candidiasis in adult non-neutropaenic patients in Spain].
García-Vargas M; Casado MA; Mir N; Barrueta JA
Farm Hosp; 2012; 36(4):207-15. PubMed ID: 22118764
[TBL] [Abstract][Full Text] [Related]
37. Pharmacology and antifungal properties of anidulafungin, a new echinocandin.
Estes KE; Penzak SR; Calis KA; Walsh TJ
Pharmacotherapy; 2009 Jan; 29(1):17-30. PubMed ID: 19113794
[TBL] [Abstract][Full Text] [Related]
38. Anidulafungin--state of affairs from a clinical perspective.
Vehreschild JJ; Kümmerle T; Karthaus M; Cornely OA
Mycoses; 2007; 50 Suppl 1():38-43. PubMed ID: 17394608
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial.
Vazquez J; Reboli AC; Pappas PG; Patterson TF; Reinhardt J; Chin-Hong P; Tobin E; Kett DH; Biswas P; Swanson R
BMC Infect Dis; 2014 Feb; 14():97. PubMed ID: 24559321
[TBL] [Abstract][Full Text] [Related]
40. Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients.
Ruhnke M; Paiva JA; Meersseman W; Pachl J; Grigoras I; Sganga G; Menichetti F; Montravers P; Auzinger G; Dimopoulos G; Borges Sá M; Miller PJ; Marček T; Kantecki M
Clin Microbiol Infect; 2012 Jul; 18(7):680-7. PubMed ID: 22404732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
